articleTop 1% cited

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Clinical Cancer Research · 2009 · Vol. 15(23) · pp. 7412–7420

Jedd D. Wolchok✉(Memorial Sloan Kettering Cancer Center)Axel Hoos(Memorial Sloan Kettering Cancer Center)Steven O’Day(Memorial Sloan Kettering Cancer Center)Jeffrey S. Weber(Bristol-Myers Squibb (United States))Omid Hamid(Memorial Sloan Kettering Cancer Center)Célèste Lebbé(Bristol-Myers Squibb (United States))Michele Maio(Memorial Sloan Kettering Cancer Center)Michael Binder(Memorial Sloan Kettering Cancer Center)Oliver Bohnsack(Memorial Sloan Kettering Cancer Center)Geoffrey Nichol(Bristol-Myers Squibb (United States))Rachel Humphrey(Memorial Sloan Kettering Cancer Center)F. Stephen Hodi(Memorial Sloan Kettering Cancer Center)

View via DOI Publisher page

Abstract

Systematic criteria, designated immune-related response criteria, were defined in an attempt to capture additional response patterns observed with immune therapy in advanced melanoma beyond those described by Response Evaluation Criteria in Solid Tumors or WHO criteria. Further prospective evaluations of the immune-related response criteria, particularly their association with overall survival, are warranted.

Immunotherapy and Immune Responses Cancer Immunotherapy and Biomarkers CAR-T cell therapy researchIpilimumabMedicineImmune systemResponse Evaluation Criteria in Solid TumorsMelanomaImmunotherapyOncologyClinical trialCancerImmunology

MeSH terms

IpilimumabAntibodies, MonoclonalAntineoplastic AgentsFemaleHumansImmunotherapyMaleMelanomaSkin NeoplasmsAntigens, CDRandomized Controlled Trials as TopicTreatment OutcomeClinical Trials, Phase II as TopicGuidelines as TopicCancer Vaccines

Citations

3,204

FWCI

27.73

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency